Last week, an agreement between the LUMC and IBLab was signed as a starting point to develop new AI tools in the field of musculoskeletal radiology. The LUMC departments of radiology and orthopedics, the Leiden University knowledge exchange office Luris and IBLab worked together in drafting this unique collaboration agreement. This strategic alliance between IB Lab and LUMC lays the foundation for new AI applications and will demonstrate their value for clinical practice.
Leiden University Medical Center (LUMC) is the university hospital affiliated with Leiden University, of which it forms the medical faculty. LUMC is a modern university medical center for research, education and patient care. Its research practice ranges from pure fundamental medical research to applied clinical research. This enables LUMC to offer patient care and education that is in line with the latest international insights and standards – and helps it to improve medicine and healthcare both internally and externally.
As an innovator, the LUMC aims to improve healthcare and people’s health by providing her patients with optimised, state-of-the-art healthcare based on pioneering research and innovative teaching.
By calling in companies and organisations in and outside the region, the LUMC makes innovations and new applications possible. The LUMC wishes to play a leading role in the development of solutions to relevant healthcare questions.
About ImageBiopsy Lab (November 2019)
ImageBiopsy Lab (IB Lab GmbH) was founded in 2016 as a spin-off of the medical technology company Braincon Technologies in Vienna. 16+ software engineers, physicians, and scientists are committed to fundamentally changing the processes, efficiency, and quality in radiology based on AI.
IB Lab is developing a novel, AI-supported modular software platform for a standardized and objective analysis of medical images. The modules of this technology platform identify/extract key radiological disease parameters that are critical for the prevention and treatment of various bone diseases. Using the FDA-cleared KOALA as an example, it is thus possible to provide a reliable support in reading knee X-ray, used by more than 50 sites worldwide every day. Additional modules for the hip and hand are also available and will be submitted later this year for the FDA review. The vision to develop and certify a focused software platform for bone diseases also convinced well-known investors such as APEX Ventures and the AWS Gründerfond, which have been on board since December 2018 as investors and fully support the further strategy of IB Lab.